Literature DB >> 9506012

Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics.

E Yukawa1, H To, S Ohdo, S Higuchi, T Aoyama.   

Abstract

Nonlinear mixed effects modeling (NONMEM) was used to estimate the effects of drug-drug interaction on valproic acid relative clearance values using 792 serum levels gathered from 400 pediatric and adult patients with epilepsy (age range, 0.3-54.8 years) during their clinical routine care. Patients received valproic acid as monopharmacy or in combination with either the antiepileptic drugs, phenobarbital, or carbamazepine. The final model describing valproic acid relative clearance was CL (mL/hr/kg) = 15.6.TBW (kg)-0.252.DOSE (mg/kg/day)0.183.0.898GEN.COPB.COCBZ, where COPB equals 1.10 if the patient is treated with phenobarbital, a value of unity otherwise, and COCBZ equals 0.769.DOSE (mg/kg/day)0.179 if the patient is treated with carbamazepine, a value of unity otherwise. Valproic acid relative clearance was highest in the very young and decreased in a weight-related fashion in children, with minimal changes observed in adults. This pattern was consistent whether valproic acid was administered alone or coadministered with phenobarbital or carbamazepine. When valproic acid was coadministered with phenobarbital or carbamazepine, valproic acid relative clearance increased as compared with that in monopharmacy. Its magnitude in the presence of carbamazepine increased in a valproic acid daily dose-related fashion. Concomitant administration of phenobarbital and valproic acid resulted in a 10% increase on valproic acid relative clearance. The clearance in female patients was approximately 10% less than that in male patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9506012     DOI: 10.1002/j.1552-4604.1997.tb04301.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  15 in total

1.  Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients.

Authors:  Jason H Williams; Bhuvaneswari Jayaraman; Kathryn J Swoboda; Jeffrey S Barrett
Journal:  J Clin Pharmacol       Date:  2011-12-13       Impact factor: 3.126

2.  Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses.

Authors:  Jae Eun Ahn; Angela K Birnbaum; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

Review 3.  Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  A systematic review of population pharmacokinetics of valproic acid.

Authors:  Janthima Methaneethorn
Journal:  Br J Clin Pharmacol       Date:  2018-02-28       Impact factor: 4.335

5.  A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.

Authors:  Junjie Ding; Yi Wang; Weiwei Lin; Changlian Wang; Limei Zhao; Xingang Li; Zhigang Zhao; Liyan Miao; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

6.  A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.

Authors:  Christelle Rodrigues; Stéphanie Chhun; Catherine Chiron; Olivier Dulac; Elisabeth Rey; Gérard Pons; Vincent Jullien
Journal:  Eur J Clin Pharmacol       Date:  2018-03-21       Impact factor: 2.953

7.  Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.

Authors:  Ehab S EL Desoky; Eliane Fuseau; Salah EL Din Amry; Valérie Cosson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-12       Impact factor: 2.953

8.  Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Jim Z Wu; Grzegorz Raszewski; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-05       Impact factor: 3.000

9.  External evaluation of a published population pharmacokinetic model of valproic acid in Thai manic patients.

Authors:  Janthima Methaneethorn; Manupat Lohitnavy
Journal:  Eur J Hosp Pharm       Date:  2018-09-26

10.  Sex related differences on valproic acid pharmacokinetics after oral single dose.

Authors:  Manuel Ibarra; Marta Vázquez; Pietro Fagiolino; Hartmut Derendorf
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-20       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.